| Literature DB >> 29579342 |
Mark A Henry1, Andrew Leung1, Christopher P Filson1.
Abstract
The rising cost of health care in the United States has been the focus of intense debate within the medical, legal, and legislative arenas, with the cost of cancer care representing an important component. Cost effectiveness is not always easy to define, and there is no standard metric in assessing this measure related to cancer therapies. Significant controversy surrounds exactly what is the appropriate cost per added year of life. This review examines cost, effectiveness, and comparative cost effectiveness of novel systemic therapies for patients with urologic malignancies. Cancer 2018;124:2897-905.Entities:
Keywords: bladder cancer; cost effectiveness; prostate cancer; renal cell cancer; systemic therapy
Mesh：
Substances：
Year: 2018 PMID： 29579342 DOI： 10.1002/cncr.31355
Source DB: PubMed Journal: Cancer ISSN： 0008-543X Impact factor: 6.860